Distinguishing APL from other AML subtypes that lack CD34 and HLA-DR expression is crucial due to the life-threatening disseminated intravascular coagulation (DIC) often associated with APL, which requires prompt treatment with ATRA and arsenic trioxide to induce the differentiation of leukemic promyelocytes [67,68]. The gene discussed is CD34; the disease is Disseminated intravascular coagulation.